Physician profile
Kenton Brown
NPI 1568542777
$1,300.95
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $157 · 2021: $360.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $255.57 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $206.06 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $121.65 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $101.61 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.31 | 2019-2020 | |
| Bausch Health US, LLC | $97.87 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $68.45 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $57.26 | 2019-2020 | |
| Allergan, INC. | $50.76 | 2019 | |
| Alfasigma USA, INC. | $50.34 | 2021 | |
| Shire North American Group INC | $40.49 | 2019 | |
| Jazz Pharmaceuticals INC. | $34.03 | 2019 | |
| Lundbeck LLC | $30.53 | 2019-2020 | |
| Abbvie INC. | $29.58 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.13 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $14.30 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.53 | 2019 | |
| Owp Pharmaceuticals, INC. | $12.48 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenton Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.